Multiple reports say AstraZeneca is in discussions about a potential merger with a US rival valued at around £300 billion. The proposed deal, if it proceeds, would be among the largest transactions ever seen in the pharmaceutical industry. According to the reporting, the combination would reshape the global market positioning of the companies involved, with the resulting group described as potentially becoming the world’s fourth-largest pharmaceutical company by size. The articles do not provide further details on which US company AstraZeneca is considering, the structure of the terms, or whether regulators have been engaged. As presented in the coverage, the development is at the “in talks” or early discussion stage rather than a finalized agreement. Any such merger would typically require due diligence and approval processes, including scrutiny by relevant competition authorities, though those steps are not detailed in the reports provided. Overall, the sources consistently describe the talks as large-scale and potentially transformational for the industry if it moves beyond preliminary negotiations.